| Literature DB >> 32848377 |
Rafał Marciniak1,2, Rastislav Šumec1,3,4, Martin Vyhnálek1, Kamila Bendíčková5, Petra Lázničková5,6, Giancarlo Forte5, Andrej Jeleník1, Veronika Římalová1,7, Jan Frič5, Jakub Hort1, Kateřina Sheardová1,3.
Abstract
BACKGROUND: Mindfulness-based programs have shown a promising effect on several health factors associated with increased risk of dementia and the conversion from mild cognitive impairment (MCI) to dementia such as depression, stress, cognitive decline, immune system and brain structural and functional changes. Studies on mindfulness in MCI subjects are sparse and frequently lack control intervention groups.Entities:
Keywords: MCI; anxiety; cognition; depression; monocyte activation; neurodegeneration
Mesh:
Year: 2020 PMID: 32848377 PMCID: PMC7429186 DOI: 10.2147/CIA.S249196
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Participant flow through the trial.
Demographics and Test Performance at Baseline (Mean, SD) for MSBR (n=12) and Control (n=8) Group
| Overall (n=20) | MBSR (n=12) | Control (n=8) | Group Effect ( | |
|---|---|---|---|---|
| Age (range 57–91 y) Mean ± SD | 74 ± 6.9 | 73.83 ± 7.04 | 74.25 ± 7.25 | 0.374 |
| Gender (Female/Male) | 13/7 | 6/6 | 7/1 | 0.213 |
| Education years | 14.3 ± 2.79 | 14.08 ± 3.08 | 14.63 ± 2.45 | 0.611 |
| MMSE Mean ± SD | 27.26 ± 1.63 | 26.82 ± 1.72 | 27.875 ± 1.36 | 0.302 |
| GDS score Mean ± SD | 4.9 ± 3.39 | 6 ± 3.19 | 3.25 ± 3.15 | 0.075 |
| BAI score Mean ± SD | 11.45 ± 11.22 | 14.92 ± 12.42 | 6.25 ± 6.92 | 0.053 |
| Shalom Mean ± SD | 36.7 ± 11.73 | 39.5 ± 10.03 | 32.5 ± 13.47 | 0.231 |
Test Performance (Median, Interquartile Range) and Results for MBSR (n=12) and Control (n=8) Group, Obtained by One-Sample Wilcoxon Test
| Baseline | Visit 2 | Visit 3 | Visit 2 vs Baseline | Visit 3 vs Baseline | |||||
|---|---|---|---|---|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |||||
| Memory score | 0.01 (−0.89–0.32) | 0.07 (−0.64–0.32) | 0.05 (−0.65–0.32) | −0.06 (−0.35–0.3) | 1 | −0.103 | −0.21 (−0.33–0.22) | 1 | −0.521 |
| Executive functions | −0.05 (−0.3–0.38) | 0.11 (−0.51–0.38) | 0.01 (−0.4–0.38) | −0.08 (−0.44–0.15) | 1 | −0.182 | −0.11 (−0.26–0.42) | 1 | −0.191 |
| Cogstate DET | 2.56 (2.52–2.68) | 2.53 (2.48–2.68) | 2.54 (2.48–2.68) | −0.04 (−0.07 – −0.02) | 0.178 | −0.685 | −0.03 (−0.08–0.02) | 0.883 | −0.306 |
| Cogstate IDN | 2.76 (2.71–2.81) | 2.72 (2.71–2.81) | 2.75 (2.73–2.81) | −0.02 (−0.04–0.01) | 0.647 | −0.53 | −0.02 (−0.05–0.01) | 1 | −0.312 |
| Cogstate OCL | 0.93 (0.86–1.04) | 0.93 (0.86–1.04) | 0.91 (0.82–1.04) | −0.01 (−0.04–0.07) | 1 | −0.114 | −0.04 (−0.11–0.02) | 1 | −0.38 |
| Cogstate ONB | 1.27 (1.15–1.39) | 1.23 (1.07–1.39) | 1.26 (1.11–1.39) | 0 (−0.09–0.11) | 1 | 0 | 0 (−0.08–0.05) | 1 | 0 |
| GDS | 5.5 (4.5–8.25) | 3 (1–8.25) | 2.5 (1–8.25) | −3.5 (−4.25 – −1.75) | −1.398 | −2 (−5.25 – −1) | −0.559 | ||
| BAI | 11 (8.25–17.5) | 10.5 (4–17.5) | 11 (7.25–17.5) | −1.5 (−10 – 4.25) | 1 | −0.147 | −1.5 (−5 – 2.75) | 1 | −0.141 |
| Memory score | 0.24 (−0.74–0.82) | 0.25 (−0.32–1.29) | 0.45 (−0.57–0.97) | 0.03 (−0.65–0.74) | 1 | 0.034 | 0.1 (−0.08–0.5) | 0.834 | 0.156 |
| Executive functions | −0.32 (−0.4–0.08) | 0 (−0.22–0.19) | −0.28 (−0.35 – −0.09) | 0.18 (−0.23–0.66) | 1 | 0.286 | −0.02 (−0.28–0.05) | 0.834 | −0.061 |
| Cogstate DET | 2.52 (2.46–2.58) | 2.53 (2.52–2.64) | 2.52 (2.47–2.6) | 0.04 (0–0.08) | 0.560 | 0.72 | −0.01 (−0.04–0.07) | 0.834 | −0.200 |
| Cogstate IDN | 2.74 (2.69–2.75) | 2.71 (2.7–2.75) | 2.73 (2.71–2.75) | 0.01 (−0.04–0.02) | 1 | 0.112 | −0.01 (−0.02–0.01) | 0.834 | −0.203 |
| Cogstate OCL | 1 (0.98–1.02) | 0.95 (0.9–0.97) | 0.85 (0.82–0.93) | −0.07 (−0.08 – −0.03) | 0.114 | −1.767 | −0.15 (−0.17 – −0.08) | 0.114 | −1.751 |
| Cogstate ONB | 1.21 (1.1–1.34) | 1.32 (1.22–1.34) | 1.16 (0.97–1.23) | −0.04 (−0.12–0.1) | 1 | −0.167 | −0.14 (−0.2 – −0.08) | 0.296 | −0.841 |
| GDS | 3 (0.75–4.5) | 2 (1.75–2.25) | 4 (1.75–5.75) | 0 (−1.25–1) | 1 | 0 | 0 (−0.25–2.5) | 0.834 | 0 |
| BAI | 5.5 (1.75–7) | 2.5 (1–9.5) | 7.5 (3.5–9.25) | −0.5 (−4 – 1.5) | 1 | −0.085 | 2 (0–2.5) | 0.338 | 0.974 |
Note: Bold formatting indicates significant results.
Abbreviations: p, adjusted p-value (Hochberg correction for multiple testing), d, effect size.
Results for MBSR (n=12) and Control (n=8) Between-Group Comparison, Obtained by Mann–Whitney Test
| MSBR vs Control Group | ||||
|---|---|---|---|---|
| Visit 2 vs Baseline | Visit 3 vs Baseline | |||
| Memory score | 0.938 | −0.124 | 0.847 | −0.616 |
| Executive functions | 0.885 | −0.494 | 0.847 | −0.195 |
| Cogstate DET | −1.429 | 0.847 | −0.187 | |
| Cogstate IDN | 0.938 | −0.560 | 0.847 | −0.099 |
| Cogstate OCL | 0.352 | 0.739 | 0.195 | 1.267 |
| Cogstate ONB | 0.938 | 0.179 | 0.847 | 0.808 |
| GDS | 0.112 | −1.464 | −0.64 | |
| BAI | 0.938 | −0.114 | 0.847 | −0.416 |
Note: Bold formatting indicates significant results.
Changes in Imunophenotype (Mean, SD) for MSBR (n=12) and Control (n=8) Group, Obtained by One-Sample Wilcoxon Test
| Baseline (Mean ± SD) | Visit 2 (Mean ± SD) | Wilcoxon Test Value | p-value | Baseline (Mean ± SD) | Visit 2 (Mean ± SD) | Wilcoxon Test Value | p-value | |
|---|---|---|---|---|---|---|---|---|
| % phagocyting cells | 15.10 ± 6.82 | 14.58 ± 9.52 | 31.00 | 0.57 | 19.61 ± 7.13 | 16.51 ± 9.60 | 4.00 | 0.22 |
| Classical (%) | 84.58 ± 4.33 | 80.14 ±5.72 | 8.00 | 0.05 | 82.21 ± 6.39 | 81.90 ± 6.49 | 7.00 | 1.00 |
| Intermediate (%) | 4.29 ± 2.05 | 5.43 ± 2.41 | 57.00 | 0.53 | 4.92 ± 2.50 | 4.45 ± 1.90 | 10.00 | 1.00 |
| Non-classical (%) | 5.05 ± 2.78 | 7.06 ± 3.74 | 67.50 | 0.08 | 6.50 ± 3.50 | 6.60 ± 2.37 | 13.00 | 1.00 |
| MHC-II on classical (GMF) | 442.00 ± 94.58 | 465.33 ± 90.98 | 50.50 | 0.39 | 466.83 ± 122.54 | 413.33 ± 99.63 | 4.00 | 0.22 |
| MHC-II on intermediate (GMF) | 1203.67 ± 298.74 | 1262.08 ± 306.91 | 43.00 | 0.79 | 1349.0 ± 368.96 | 1363.83 ± 318.88 | 12.00 | 0.84 |
| MHC-II on non-classical (GMF) | 608.33 ± 202.94 | 580.25 ± 168.65 | 27.00 | 0.38 | 692.33 ± 236.97 | 629.67 ± 190.19 | 5.00 | 0.31 |
| CD86 on classical (GMF) | ||||||||
| CD86 on intermediate (GMF) | 535.50 ± 81.35 | 494.50 ± 79.41 | 1.00 | 0.06 | ||||
| CD86 on non-classical (GMF) | 393.50 ± 117.62 | 357.17 ± 84.07 | 23.50 | 0.24 | 384.0 ± 100.02 | 371.17 ± 48.76 | 6.00 | 0.40 |
| hsCRP (mg/l) | 1.57 ± 1.65 | 1.49 ± 1.55 | −11.00 | 0.63 | 1.72 ± 1.66 | 1.15 ± 1.62 | −7.00 | 0.56 |
| IL-6 (pg/mL) | 1.57 ± 0.65 | 2.00 ± 1.31 | 24.00 | 0.32 | 2.40 ± 1.82 | 2.48 ± 2.86 | 2.00 | 0.95 |
| TNF-α (pg/mL) | 1.12 ± 0.32 | 1.29 ± 0.44 | 38.00 | 0.10 | 1.07 ± 0.38 | 1.02 ± 0.37 | −20.00 | 0.20 |
Note: Bold formatting indicates significant results.
Figure 2Adherence to home practice (A), the most and the least popular practices (B), the most appreciated aspects of MBSR (C) and the challenging aspects of MBSR (D).